Developer docs
API playgroundTry for free, no card

Search company profiles

Singlera Genomics

Full company profile

uuid0000d5f

Namestring
Singlera Genomics
Legal namestring
Singlera Genomics Inc.
Websiteurl
singlera.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Singlera Genomics Inc., founded in 2014 and headquartered in La Jolla, California with additional offices in Chengdu, Shanghai, Taizhou, and Yangzhou, is a privately held molecular diagnostics company developing non-invasive liquid biopsy tests for early cancer detection. Its core technology is circulating tumor DNA (ctDNA) methylation analysis, built around three proprietary platforms: mTitan (targeted methylation detection with a single-day workflow and up to 80% molecular conversion rate), mGuard (multi-gene methylation liquid biopsy with detection limits as low as 0.05%), and MONOD (whole-genome methylation enrichment scanning via methylation haplotype analysis). The commercial product portfolio includes ColonAiQ (NMPA Class III-certified colorectal cancer screening), ColonES, GutSeer (multi-gastrointestinal cancer detection across five cancer types), PDACatch (FDA Breakthrough Device Designation for pancreatic adenocarcinoma), Personalized MRD for treatment monitoring, POCT kits, and the CaptureRevo NAE24 nucleic acid extraction instrument.

Singlera serves three primary customer segments: healthcare providers and medical laboratories offering early cancer screening and prognostic monitoring to high-risk patients, pharmaceutical companies such as Astellas pursuing methylation-based research tools and companion diagnostics, and academic institutions such as Fudan University, the University of Pittsburgh, UCSD, and Xiang Ya Hospital for large-scale cancer screening studies including the 200,000-volunteer Taizhou Longitudinal Study. Revenue is generated through a partner-led distribution model rather than direct sales, with products commercialized as Laboratory Developed Tests (LDTs) by CAP/CLIA-certified partners (Breakthrough Genomics in California, Clinomics USA), via European distribution and research agreements (Pure Medical), and through research collaborations and potential milestone payments with pharmaceutical partners. The company has raised approximately $230 million+ across disclosed funding rounds and reports a workforce of 101-250 employees.

Short descriptiontext

Singlera Genomics is a privately held molecular diagnostics company developing non-invasive liquid biopsy tests for early cancer detection using proprietary ctDNA methylation platforms (mTitan, mGuard, MONOD), serving laboratories, pharmaceutical companies, and academic researchers across the US, China, and Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLa Jolla, United States
HQ citystring
La Jolla
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
liquid biopsy diagnostics, early cancer detection, DNA methylation analysis, non-invasive genetic testing, circulating tumor DNA
Industry5 codes
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code4 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical and Diagnostic Laboratories6215
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Laboratory Analytical Instruments3826
Product category
Cancer Diagnostics and Liquid Biopsy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Testing Services
TypeOne Time License
Description

Singlera provides cancer detection tests through partner laboratories as Laboratory Developed Tests (LDTs). Partners including Breakthrough Genomics and Clinomics offer Singlera's products including ColonES, PDACatch, and PanSeer through their CAP and CLIA-certified labs in the US and globally.

singlera.com
2Product Distribution Agreements
TypeOne Time License
Description

European distribution and research agreement with Pure Medical to distribute cancer detection assays across European countries. Revenue generated from sale of assay products including mTitan and mGuard-based products.

biospace.com
3Pharmaceutical Research Collaborations
TypeLicensing Royalties
Description

Collaborations with pharmaceutical companies like Astellas for methylation-based research tools to understand biological reactions to pharmaceuticals. May include milestone payments and research funding.

singlera.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 11 records shown
1PDACatch
Description

Liquid biopsy assay for early detection of pancreatic adenocarcinoma (PDAC) in high-risk individuals, granted FDA Breakthrough Device Designation

singlera.com
+10 more records
Core offering1 text field

Singlera Genomics develops and commercializes non-invasive liquid biopsy tests for early cancer detection using proprietary circulating tumor DNA (ctDNA) methylation analysis. The company offers a portfolio of blood-based diagnostic products (ColonAiQ, ColonES, GutSeer, PDACatch, PanSeer, Personalized MRD) built on three technology platforms (mTitan, mGuard, MONOD) and distributes them through partner laboratories and distribution agreements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Detected cancer signals 4+ years before conventional diagnosis using blood test
+4 more records
Product overview1 text field

Singlera Genomics offers a comprehensive portfolio of cancer early detection and diagnostic products built on three core technology platforms: mTitan (targeted methylation detection with single-day workflow), mGuard (multi-gene methylation liquid biopsy with 3-20 gene detection), and MONOD (whole genome methylation enrichment). The product lineup centers on liquid biopsy tests for early cancer detection including ColonAiQ (colorectal cancer, NMPA-certified), ColonES (colorectal cancer via NGS), GutSeer (gastrointestinal cancers covering 5 cancer types), and PDACatch (pancreatic cancer, FDA Breakthrough Device Designation). Supporting offerings include Personalized MRD for treatment monitoring, POCT kits for point-of-care testing, and CaptureRevo NAE24 automated nucleic acid extraction system. The company serves the global market through distribution partnerships and laboratory services.

Product and service9 records
1PDACatch
CategoryCancer Diagnostics
Description

Liquid biopsy assay with FDA Breakthrough Device Designation for early detection of pancreatic adenocarcinoma (PDAC) in high-risk individuals, using proprietary DNA methylation technology on circulating tumor DNA. Demonstrated ability to detect cancer four years before conventional methods.

2ColonAiQ
CategoryCancer Diagnostics
Description

Multi-locus blood-based assay targeting circulating tumor DNA methylation for non-invasive early detection of colorectal cancer and advanced adenoma. NMPA Class III medical device registered.

3ColonES
CategoryCancer Diagnostics
Description

Blood-based colorectal cancer screening assay using circulating tumor DNA methylation signals captured via high-throughput next-generation sequencing, offering superior sensitivity and specificity compared to stool-based methods.

4GutSeer
CategoryCancer Diagnostics
Description

Non-invasive blood-based assay for early detection and localization of gastrointestinal cancers using cell-free DNA methylation and fragmentation signatures across a 1656 target region panel, covering colorectal, gastric, liver, esophageal, and pancreatic cancers.

5Personalized MRD
CategoryCancer Diagnostics
Description

Liquid biopsy assay for personalized minimal residual disease monitoring and relapse prediction. Analyzes DNA methylation alterations and fragmentation patterns in circulating tumor DNA to distinguish cancerous from non-cancerous cell-free DNA.

6POCT Kits
CategoryPoint-of-Care Diagnostics
Description

Point-of-care testing kits including Fecal Occult Blood Diagnostic Test, Fecal Occult Blood and Transferrin Diagnostic Test, and H.Pylori Antigen Diagnostic Test, using colloidal gold method for rapid results.

7CaptureRevo NAE24
CategoryLaboratory Instruments
Description

Automated nucleic acid extraction system using magnetic bead-based technology with touch screen interface, UV sterilization, heating up to 120°C, completing extraction in 10-60 minutes per run with Ethernet and Wi-Fi connectivity.

8PanSeer
CategoryCancer Diagnostics
Description

Pan-cancer screening technology for early detection of multiple cancer types from a single blood test.

9BT-Reveal
CategoryCancer Diagnostics
Description

Early pancreatic cancer test offered by Breakthrough Genomics using PDACatch technology. Detects early stages of pancreatic cancer from a simple blood draw, identifying cancer signals before symptoms appear.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-23
Description

European distribution and research agreement with Pure Medical, a European-based medical company. Collaboration on cancer detection research and distribution of assays including mTitan and mGuard across several European countries. Aims to facilitate early, non-invasive detection of various cancers.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-17
Description

Research collaboration with University of Pittsburgh and Breakthrough Genomics to evaluate BT-Reveal early pancreatic cancer test. Test utilizes DNA methylation technology on mTitan platform to detect cancer signals in circulating DNA before symptoms appear. Preclinical study step towards larger FDA longitudinal study for pancreatic cancer screening.

3Breakthrough Genomics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-06
Description

Strategic cooperation agreement for pancreatic cancer screening service in California. Singlera provides technical support using PDACatch technology. Breakthrough Genomics operates CAP and CLIA-certified genomics laboratory in Irvine offering LDT services. Strategic cooperation agreement signed in 2022.

singlera.com
4Clinomics USA
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-04-28
Description

Strategic cooperation agreement with Clinomics USA (South Korean company Clinomics subsidiary) for early cancer detection services. Plans to establish global strategic partnership for early cancer detection based on liquid biopsy. Launching ColonES, PDACatch, and PanSeer testing services through Clinomics Irvine CLIA Lab.

singlera.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-04-05
Description

Research collaboration with Astellas Pharma pursuing methylation-based tools to better understand biological reactions to pharmaceuticals. Part of Astellas's research efforts to develop companion diagnostics and understand drug response mechanisms.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2016-07-18
Description

Longitudinal study collaboration with Fudan University on 200,000 volunteer cohort (Taizhou Longitudinal Study). Joint research demonstrating detection of five common cancers earlier than standard tests and pan-cancer early detection results published in Nature Communications.

7Fudan Taizou Institute
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Research partnership with Fudan Taizou Institute for cancer early detection studies.

singlera.com
8University of California San Diego
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partnership with UCSD for genomics research collaboration.

singlera.com
9Xiang Ya Hospital
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical partnership with Xiang Ya Hospital for cancer diagnostics research.

singlera.com
10Clinomics
Strategic tierCoreTypeStrategic or Co-development Partner
Description

South Korean biomedical innovation company dedicated to liquid biopsy and multi-omics-based early cancer diagnostic technologies. Strategic partner for global market expansion including US, Europe, Japan, and South Korea markets.

singlera.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling of solid tumors using circulating and tissue-based DNA/RNA assays. While broader than Singlera's methylation focus, Foundation Medicine overlaps significantly in oncology molecular diagnostics and uses similar NGS-based ctDNA workflows.

TypeDirect peer
Description

Natera's Signatera is a leading personalized MRD test using tumor-informed ctDNA analysis. Singlera's Personalized MRD product uses methylation-based (rather than mutation-based) ctDNA signatures to perform the same minimal residual disease monitoring function for oncology patients.

TypeDirect peer
Description

Guardant Health is a leading liquid biopsy company offering Guardant360 for tumor mutation profiling and Guardant Reveal for MRD, both based on circulating tumor DNA. Singlera's methylation-based ctDNA tests and Personalized MRD product directly compete in the same oncology liquid biopsy space.

4GRAIL
TypeDirect peer
Description

GRAIL is the most direct multi-cancer early detection (MCED) competitor, developing the Galleri blood test that screens for multiple cancer signals from a single draw. Like Singlera, GRAIL uses next-generation sequencing on blood-derived cell-free DNA and targets the same MCED market segment.

TypeEmerging player
Description

Personalis provides ultra-sensitive ctDNA-based MRD (NeXT Personal) and tumor profiling services, primarily through pharma and clinical research channels. Personalis's MRD focus and ultra-sensitive ctDNA detection compete with Singlera's Personalized MRD and methylation-based approaches.

TypeDirect peer
Description

Exact Sciences markets Cologuard, the leading non-invasive colorectal cancer screening test, and acquired Thrive Earlier Detection to enter MCED. Singlera's ColonES, ColonAiQ, and GutSeer compete directly with Cologuard in colorectal screening and with Thrive's CancerSEEK in MCED.

TypeBroad incumbent
Description

NeoGenomics operates a global oncology testing laboratory network offering liquid biopsy, molecular diagnostics, and pathology services through its Pharma Services and Clinical Services divisions. Its RaDaR MRD assay and broad oncology menu make it a broad incumbent competing across Singlera's product portfolio.

TypeRegional player
Description

Burning Rock is a China-based oncology liquid biopsy company offering cancer therapy selection and MRD tests using NGS-based ctDNA analysis. It directly competes with Singlera's methylation-based ctDNA products in the Chinese market where Singlera also operates.

TypeDirect peer
Description

Freenome is a multiomics liquid biopsy company developing tests for early cancer detection using cfDNA, methylomics, and proteomics. Freenome's first product targets colorectal cancer screening, directly competing with Singlera's ColonES and ColonAiQ.

10Genetron Holdings
TypeRegional player
Description

Genetron is a China-based precision oncology company offering NGS-based cancer screening, diagnosis, and monitoring products, including MRD and early detection assays. Genetron directly competes with Singlera in the Chinese oncology liquid biopsy market with similar ctDNA-based approaches.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors24 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Singlera Genomics

Cancer Diagnostics and Liquid Biopsysinglera.com

Singlera Genomics is a privately held molecular diagnostics company developing non-invasive liquid biopsy tests for early cancer detection using proprietary ctDNA methylation platforms (mTitan, mGuard, MONOD), serving laboratories, pharmaceutical companies, and academic researchers across the US, China, and Europe.

What Singlera Genomics does

Singlera Genomics Inc., founded in 2014 and headquartered in La Jolla, California with additional offices in Chengdu, Shanghai, Taizhou, and Yangzhou, is a privately held molecular diagnostics company developing non-invasive liquid biopsy tests for early cancer detection. Its core technology is circulating tumor DNA (ctDNA) methylation analysis, built around three proprietary platforms: mTitan (targeted methylation detection with a single-day workflow and up to 80% molecular conversion rate), mGuard (multi-gene methylation liquid biopsy with detection limits as low as 0.05%), and MONOD (whole-genome methylation enrichment scanning via methylation haplotype analysis). The commercial product portfolio includes ColonAiQ (NMPA Class III-certified colorectal cancer screening), ColonES, GutSeer (multi-gastrointestinal cancer detection across five cancer types), PDACatch (FDA Breakthrough Device Designation for pancreatic adenocarcinoma), Personalized MRD for treatment monitoring, POCT kits, and the CaptureRevo NAE24 nucleic acid extraction instrument.

Singlera serves three primary customer segments: healthcare providers and medical laboratories offering early cancer screening and prognostic monitoring to high-risk patients, pharmaceutical companies such as Astellas pursuing methylation-based research tools and companion diagnostics, and academic institutions such as Fudan University, the University of Pittsburgh, UCSD, and Xiang Ya Hospital for large-scale cancer screening studies including the 200,000-volunteer Taizhou Longitudinal Study. Revenue is generated through a partner-led distribution model rather than direct sales, with products commercialized as Laboratory Developed Tests (LDTs) by CAP/CLIA-certified partners (Breakthrough Genomics in California, Clinomics USA), via European distribution and research agreements (Pure Medical), and through research collaborations and potential milestone payments with pharmaceutical partners. The company has raised approximately $230 million+ across disclosed funding rounds and reports a workforce of 101-250 employees.

Singlera Genomics firmographics

Firmographics
Name
Singlera Genomics
Legal name
Singlera Genomics Inc.
Website
https://singlera.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Singlera Genomics is a privately held molecular diagnostics company developing non-invasive liquid biopsy tests for early cancer detection using proprietary ctDNA methylation platforms (mTitan, mGuard, MONOD), serving laboratories, pharmaceutical companies, and academic researchers across the US, China, and Europe.
Ownership category
akta.pro rank

Singlera Genomics industry classification

Industry
Product category
Cancer Diagnostics and Liquid Biopsy
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Liquid biopsy diagnostics
  • Early cancer detection
  • DNA methylation analysis
  • Non-invasive genetic testing
  • Circulating tumor DNA

Where Singlera Genomics is headquartered

Location

Headquarters

HQ city
La Jolla
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Singlera Genomics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Testing Services: Singlera provides cancer detection tests through partner laboratories as Laboratory Developed Tests (LDTs). Partners including Breakthrough Genomics and Clinomics offer Singlera's products including ColonES, PDACatch, and PanSeer through their CAP and CLIA-certified labs in the US and globally.
  2. Product Distribution Agreements: European distribution and research agreement with Pure Medical to distribute cancer detection assays across European countries. Revenue generated from sale of assay products including mTitan and mGuard-based products.
  3. Pharmaceutical Research Collaborations: Collaborations with pharmaceutical companies like Astellas for methylation-based research tools to understand biological reactions to pharmaceuticals. May include milestone payments and research funding.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Singlera Genomics product offering

Product offering

Core offering

Singlera Genomics develops and commercializes non-invasive liquid biopsy tests for early cancer detection using proprietary circulating tumor DNA (ctDNA) methylation analysis. The company offers a portfolio of blood-based diagnostic products (ColonAiQ, ColonES, GutSeer, PDACatch, PanSeer, Personalized MRD) built on three technology platforms (mTitan, mGuard, MONOD) and distributes them through partner laboratories and distribution agreements.

Product overview

Singlera Genomics offers a comprehensive portfolio of cancer early detection and diagnostic products built on three core technology platforms: mTitan (targeted methylation detection with single-day workflow), mGuard (multi-gene methylation liquid biopsy with 3-20 gene detection), and MONOD (whole genome methylation enrichment). The product lineup centers on liquid biopsy tests for early cancer detection including ColonAiQ (colorectal cancer, NMPA-certified), ColonES (colorectal cancer via NGS), GutSeer (gastrointestinal cancers covering 5 cancer types), and PDACatch (pancreatic cancer, FDA Breakthrough Device Designation). Supporting offerings include Personalized MRD for treatment monitoring, POCT kits for point-of-care testing, and CaptureRevo NAE24 automated nucleic acid extraction system. The company serves the global market through distribution partnerships and laboratory services.

Differentiator

Problem solved

Functional benefit

Brands

  • PDACatch: Liquid biopsy assay for early detection of pancreatic adenocarcinoma (PDAC) in high-risk individuals, granted FDA Breakthrough Device Designation
  • ColonAiQ
  • ColonES
  • GutSeer
  • BT-Reveal
  • PanSeer
  • mTitan
  • mGuard
  • MONOD
  • CaptureRevo
  • Gutfocus

Products and services

  • PDACatch Liquid biopsy assay with FDA Breakthrough Device Designation for early detection of pancreatic adenocarcinoma (PDAC) in high-risk individuals, using proprietary DNA methylation technology on circulating tumor DNA. Demonstrated ability to detect cancer four years before conventional methods.
  • ColonAiQ Multi-locus blood-based assay targeting circulating tumor DNA methylation for non-invasive early detection of colorectal cancer and advanced adenoma. NMPA Class III medical device registered.
  • ColonES Blood-based colorectal cancer screening assay using circulating tumor DNA methylation signals captured via high-throughput next-generation sequencing, offering superior sensitivity and specificity compared to stool-based methods.
  • GutSeer Non-invasive blood-based assay for early detection and localization of gastrointestinal cancers using cell-free DNA methylation and fragmentation signatures across a 1656 target region panel, covering colorectal, gastric, liver, esophageal, and pancreatic cancers.
  • Personalized MRD Liquid biopsy assay for personalized minimal residual disease monitoring and relapse prediction. Analyzes DNA methylation alterations and fragmentation patterns in circulating tumor DNA to distinguish cancerous from non-cancerous cell-free DNA.
  • POCT Kits Point-of-care testing kits including Fecal Occult Blood Diagnostic Test, Fecal Occult Blood and Transferrin Diagnostic Test, and H.Pylori Antigen Diagnostic Test, using colloidal gold method for rapid results.
  • CaptureRevo NAE24 Automated nucleic acid extraction system using magnetic bead-based technology with touch screen interface, UV sterilization, heating up to 120°C, completing extraction in 10-60 minutes per run with Ethernet and Wi-Fi connectivity.
  • PanSeer Pan-cancer screening technology for early detection of multiple cancer types from a single blood test.
  • BT-Reveal Early pancreatic cancer test offered by Breakthrough Genomics using PDACatch technology. Detects early stages of pancreatic cancer from a simple blood draw, identifying cancer signals before symptoms appear.

Quantifiable outcome

  • Detected cancer signals 4+ years before conventional diagnosis using blood test
  • +4 more outcomes

Companies that use Singlera Genomics

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Singlera Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature9 records

Singlera Genomics partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, major and minor.

  • Pure MedicalcoreChannel Partner/ Reseller/ Distributor · 23 December 2025European distribution and research agreement with Pure Medical, a European-based medical company. Collaboration on cancer detection research and distribution of assays including mTitan and mGuard across several European countries. Aims to facilitate early, non-invasive detection of various cancers.
  • University of PittsburghcoreStrategic or Co-development Partner · 17 December 2025Research collaboration with University of Pittsburgh and Breakthrough Genomics to evaluate BT-Reveal early pancreatic cancer test. Test utilizes DNA methylation technology on mTitan platform to detect cancer signals in circulating DNA before symptoms appear. Preclinical study step towards larger FDA longitudinal study for pancreatic cancer screening.
  • Breakthrough GenomicscoreStrategic or Co-development Partner · 6 May 2023Strategic cooperation agreement for pancreatic cancer screening service in California. Singlera provides technical support using PDACatch technology. Breakthrough Genomics operates CAP and CLIA-certified genomics laboratory in Irvine offering LDT services. Strategic cooperation agreement signed in 2022.
  • Clinomics USAcoreStrategic or Co-development Partner · 28 April 2023Strategic cooperation agreement with Clinomics USA (South Korean company Clinomics subsidiary) for early cancer detection services. Plans to establish global strategic partnership for early cancer detection based on liquid biopsy. Launching ColonES, PDACatch, and PanSeer testing services through Clinomics Irvine CLIA Lab.
  • Astellas PharmamajorStrategic or Co-development Partner · 5 April 2022Research collaboration with Astellas Pharma pursuing methylation-based tools to better understand biological reactions to pharmaceuticals. Part of Astellas's research efforts to develop companion diagnostics and understand drug response mechanisms.
  • Fudan UniversitymajorStrategic or Co-development Partner · 18 July 2016Longitudinal study collaboration with Fudan University on 200,000 volunteer cohort (Taizhou Longitudinal Study). Joint research demonstrating detection of five common cancers earlier than standard tests and pan-cancer early detection results published in Nature Communications.
  • Fudan Taizou InstitutemajorStrategic or Co-development PartnerResearch partnership with Fudan Taizou Institute for cancer early detection studies.
  • University of California San DiegominorStrategic or Co-development PartnerAcademic partnership with UCSD for genomics research collaboration.
  • Xiang Ya HospitalminorStrategic or Co-development PartnerClinical partnership with Xiang Ya Hospital for cancer diagnostics research.
  • ClinomicscoreStrategic or Co-development PartnerSouth Korean biomedical innovation company dedicated to liquid biopsy and multi-omics-based early cancer diagnostic technologies. Strategic partner for global market expansion including US, Europe, Japan, and South Korea markets.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Singlera Genomics competitors and assessment

Company assessment

Broad incumbents

  • Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling of solid tumors using circulating and tissue-based DNA/RNA assays. While broader than Singlera's methylation focus, Foundation Medicine overlaps significantly in oncology molecular diagnostics and uses similar NGS-based ctDNA workflows.
  • NeoGenomics: NeoGenomics operates a global oncology testing laboratory network offering liquid biopsy, molecular diagnostics, and pathology services through its Pharma Services and Clinical Services divisions. Its RaDaR MRD assay and broad oncology menu make it a broad incumbent competing across Singlera's product portfolio.

Direct peers

  • Natera: Natera's Signatera is a leading personalized MRD test using tumor-informed ctDNA analysis. Singlera's Personalized MRD product uses methylation-based (rather than mutation-based) ctDNA signatures to perform the same minimal residual disease monitoring function for oncology patients.
  • Guardant Health: Guardant Health is a leading liquid biopsy company offering Guardant360 for tumor mutation profiling and Guardant Reveal for MRD, both based on circulating tumor DNA. Singlera's methylation-based ctDNA tests and Personalized MRD product directly compete in the same oncology liquid biopsy space.
  • GRAIL: GRAIL is the most direct multi-cancer early detection (MCED) competitor, developing the Galleri blood test that screens for multiple cancer signals from a single draw. Like Singlera, GRAIL uses next-generation sequencing on blood-derived cell-free DNA and targets the same MCED market segment.
  • Exact Sciences: Exact Sciences markets Cologuard, the leading non-invasive colorectal cancer screening test, and acquired Thrive Earlier Detection to enter MCED. Singlera's ColonES, ColonAiQ, and GutSeer compete directly with Cologuard in colorectal screening and with Thrive's CancerSEEK in MCED.
  • Freenome: Freenome is a multiomics liquid biopsy company developing tests for early cancer detection using cfDNA, methylomics, and proteomics. Freenome's first product targets colorectal cancer screening, directly competing with Singlera's ColonES and ColonAiQ.

Emerging players

  • Personalis: Personalis provides ultra-sensitive ctDNA-based MRD (NeXT Personal) and tumor profiling services, primarily through pharma and clinical research channels. Personalis's MRD focus and ultra-sensitive ctDNA detection compete with Singlera's Personalized MRD and methylation-based approaches.

Regional players

  • Burning Rock Biotech: Burning Rock is a China-based oncology liquid biopsy company offering cancer therapy selection and MRD tests using NGS-based ctDNA analysis. It directly competes with Singlera's methylation-based ctDNA products in the Chinese market where Singlera also operates.
  • Genetron Holdings: Genetron is a China-based precision oncology company offering NGS-based cancer screening, diagnosis, and monitoring products, including MRD and early detection assays. Genetron directly competes with Singlera in the Chinese oncology liquid biopsy market with similar ctDNA-based approaches.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Singlera Genomics social profiles

Digital presence

Singlera Genomics compliance and trust

Trust signal

Compliance2 records

Singlera Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Singlera Genomics leadership team

Management profile

Number of profiles

Profiles5 records

Singlera Genomics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Singlera Genomics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors24 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Singlera Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Singlera Genomics

What does Singlera Genomics do?

Singlera Genomics develops and commercializes non-invasive liquid biopsy tests for early cancer detection using proprietary circulating tumor DNA (ctDNA) methylation analysis. The company offers a portfolio of blood-based diagnostic products (ColonAiQ, ColonES, GutSeer, PDACatch, PanSeer, Personalized MRD) built on three technology platforms (mTitan, mGuard, MONOD) and distributes them through partner laboratories and distribution agreements.

Is Singlera Genomics a public or private company?

Singlera Genomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Singlera Genomics founded?

Singlera Genomics was founded in 2014. It employs 11 to 50 people.

Where is Singlera Genomics based?

Singlera Genomics is headquartered in La Jolla, United States, in the North America region.

How does Singlera Genomics make money?

Three revenue lines are on record. Diagnostic Testing Services are the primary driver. The others are product Distribution Agreements and pharmaceutical Research Collaborations.

Who are Singlera Genomics's main competitors?

Broad incumbents on record are Foundation Medicine and NeoGenomics. Direct peers are Natera, Guardant Health, GRAIL, Exact Sciences and Freenome. Personalis is listed as an emerging player. Regional players are Burning Rock Biotech and Genetron Holdings.

Does Singlera Genomics have an API?

No public API is recorded for Singlera Genomics.

What industry is Singlera Genomics in?

Singlera Genomics's product category is Cancer Diagnostics and Liquid Biopsy. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceSinglera Genomics Signs European Distribution and Research Agreement with Pure Medical for Cancer Detection ProductsSinglera Genomics has entered into a research and distribution agreement with European Union-based Pure Medical to commercialize its mTitan and mGuard cancer detection platforms across western Europe. The partnership involves collaboration with universities, hospital networks, and national healthcare systems for research studies and commercial distribution of non-invasive assays that screen circulating cell-free DNA for early detection of esophageal, colorectal, gastric, lung, liver, and pancreatic cancer. The agreement represents Singlera\u2019s strategic expansion into the European market, with commercialization planned across seven EU countries and existing research collaborations in the UK.GlobeNewswireSinglera Genomics Signs European Distribution and Research Agreement with Pure Medical for Cancer Detection ProductsSinglera Genomics has entered into a research and distribution agreement with European medical company Pure Medical to commercialize its mTitan and mGuard cancer detection platforms in western Europe. The partnership involves collaborating with local universities, hospital networks, and national healthcare systems on research studies while distributing assays for colorectal and pancreatic cancers across seven EU countries. This strategic move aims to bring inexpensive early cancer detection tools to the global patient population and support faster diagnosis and treatment.SdbnSinglera Genomics announces research collaboration with the University of Pittsburgh to advance pancreatic cancer early detection – San Diego Biotechnology NetworkSinglera Genomics announced a research collaboration with the University of Pittsburgh and partner Breakthrough Genomics to advance preclinical evaluation of their BT-Reveal Early Pancreatic Cancer Test. The partnership leverages Singlera's DNA methylation technologies and Breakthrough's genomic data analysis capabilities for early cancer diagnostics development. This collaboration represents a strategic effort to accelerate development of a non-invasive test for pancreatic cancer detection.GlobeNewswireSinglera Genomics announces research collaboration with the University of Pittsburgh to advance pancreatic cancer early detectionSinglera Genomics, in partnership with Breakthrough Genomics, announced a research collaboration with the University of Pittsburgh to conduct preclinical evaluation of their BT-Reveal™ Early Pancreatic Cancer Test. The blood test uses Singlera's mTitan platform to screen circulating cell-free DNA for cancer signals before symptoms appear and has already received FDA Breakthrough Device Designation. The collaboration aims to advance toward a full large-scale FDA longitudinal study for pancreatic cancer screening in high-risk populations.GlobeNewswireSinglera Genomics and Partners publish results from GUIDE prospective cohort study demonstrating blood-based early detection of gastrointestinal cancers using DNA methylation-based GutSeer assaySinglera Genomics and Fudan University's Zhongshan Hospital published results from the GUIDE prospective cohort study, showing the GutSeer blood test detects five gastrointestinal cancers at early stage. The assay achieved 81.5% sensitivity and 94.4% specificity, and outperformed a low-pass WGS fragmentomics assay in AUC.GlobeNewswireSinglera Genomics and Partners publish results from GUIDE prospective cohort study demonstrating blood-based early detection of gastrointestinal cancers using DNA methylation-based GutSeer assaySinglera Genomics and Fudan University's Zhongshan Hospital published results from the GUIDE prospective cohort study, showing the GutSeer blood test detects five gastrointestinal cancers at early stage. The assay achieved 81.5% sensitivity and 94.4% specificity, and outperformed a low-pass WGS fragmentomics assay in AUC.GlobeNewswireSinglera Genomics Presented Non-Invasive Testicular Toxicity Detection with Astellas at 2025 SOT MeetingSinglera Genomics and Astellas presented results at the 2025 SOT meeting showing a refined approach to detect drug-induced testicular toxicity using cell-free DNA methylation. The mTitan technology detected methylation signals in rats treated with a toxic compound, enabling early detection without invasive pathology. The company said the results could expedite drug development pipelines.GlobeNewswireSinglera Genomics presents results of PDACatch preclinical study at HM Hospitals Annual Early Detection MeetingSinglera Genomics presented preclinical results of its PDACatch assay at HM Hospitals' annual meeting, showing non-invasive retrospective detection of early-stage pancreatic cancer in high-risk patients. The company plans a clinical trial for FDA pre-market approval and EU certification.PR NewswireSinglera Genomics Receives FDA Breakthrough Device Designation for PDACatch, a Liquid Biopsy Assay for Pancreatic Cancer Detection in High-Risk IndividualsSinglera Genomics has received Breakthrough Device Designation from the U.S. Food and Drug Administration for its PDACatch assay, a DNA methylation-based liquid biopsy test for detecting pancreatic adenocarcinoma in high-risk individuals. PDACatch is the first liquid biopsy tool capable of detecting and monitoring pancreatic cancer, addressing a disease with a less than 10% five-year survival rate largely due to late-stage diagnosis. The FDA designation enables prioritized review and could accelerate the assay's path to market following ongoing clinical trials and pre-market approval processes.PR NewswireMulti Cancer Early Detection Market Worth $2.77 Billion by 2030: Grand View Research, Inc.Grand View Research released a market report projecting the global multi cancer early detection (MCED) market to reach $2.77 billion by 2030, growing at a compound annual growth rate of 15.80% from 2022 to 2030, driven by rising cancer prevalence and the need for early diagnosis. The report highlights GRAIL's Galleri as the first commercially available MCED screening test in the U.S. market, while noting that Exact Sciences, Freenome, and other companies are also developing competing tests. Key developments cited include Singlera Genomics raising $150 million in Series B funding in December 2020 and GRAIL partnering with Point32Health for a pilot program, with North America expected to be the fastest-growing regional market.